Literature DB >> 12117678

Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology.

F Buttgereit1, J A P da Silva, M Boers, G-R Burmester, M Cutolo, J Jacobs, J Kirwan, L Köhler, P Van Riel, T Vischer, J W J Bijlsma.   

Abstract

In rheumatology and other medical specialties there is a discrepancy between the widespread use and the imprecise designation of glucocorticoid treatment regimens. Verbal descriptions of glucocorticoid treatment regimens used in various phases of diseases vary between countries and institutions. Given this background, a workshop under the auspices of the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials was held to discuss this issue and to seek a consensus on nomenclature for glucocorticoid treatment. This report summarises the panel's discussion and recognises that answers derived from consensus conferences are not definitive. Nevertheless, recommendations on glucocorticoid treatment are presented that (1) reflect current and best knowledge available and (2) take into account current clinical practice. A question-answer rationale presentation style has been chosen to convey the messages, to summarise the meeting in a readable format, and to avoid dogmatism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117678      PMCID: PMC1754188          DOI: 10.1136/ard.61.8.718

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

Review 1.  Bioenergetics of immune functions: fundamental and therapeutic aspects.

Authors:  F Buttgereit; G R Burmester; M D Brand
Journal:  Immunol Today       Date:  2000-04

2.  Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states.

Authors:  D Schmid; G R Burmester; R Tripmacher; A Kuhnke; F Buttgereit
Journal:  Biosci Rep       Date:  2000-08       Impact factor: 3.840

3.  Therapeutic implications of non-genomic glucocorticoid activity.

Authors:  B J Lipworth
Journal:  Lancet       Date:  2000-07-08       Impact factor: 79.321

4.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

Authors:  M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden
Journal:  Lancet       Date:  1997-08-02       Impact factor: 79.321

Review 5.  Involvement of the hypothalamic--pituitary--adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role.

Authors:  R H Straub; M Cutolo
Journal:  Arthritis Rheum       Date:  2001-03

Review 6.  Corticosteroids in polymyalgia rheumatica--a review of different treatment schedules.

Authors:  C Li; B Dasgupta
Journal:  Clin Exp Rheumatol       Date:  2000 Jul-Aug       Impact factor: 4.473

Review 7.  Optimizing glucocorticoid therapy in rheumatoid arthritis.

Authors:  J A Da Silva; J W Bijlsma
Journal:  Rheum Dis Clin North Am       Date:  2000-11       Impact factor: 2.670

8.  Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Amalia A van Everdingen; Johannes W G Jacobs; Dirk R Siewertsz Van Reesema; Johannes W J Bijlsma
Journal:  Ann Intern Med       Date:  2002-01-01       Impact factor: 25.391

9.  Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids.

Authors:  M Cutolo; L Foppiani; C Prete; P Ballarino; A Sulli; B Villaggio; B Seriolo; M Giusti; S Accardo
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

10.  Neuropsychiatric Systemic Lupus Erythematosus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.972

View more
  114 in total

1.  Circadian rhythms in RA.

Authors:  M Cutolo; B Seriolo; C Craviotto; C Pizzorni; A Sulli
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

2.  Glucocorticoids in the treatment of early and late RA.

Authors:  J W J Bijlsma; M Boers; K G Saag; D E Furst
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 3.  [Glucocorticoid therapy in collagen diseases diseases].

Authors:  L Unger; M Kayser; M Enderlein; K Manger; H Nüsslein
Journal:  Z Rheumatol       Date:  2005-04       Impact factor: 1.372

4.  Pulse steroid therapy.

Authors:  Aditi Sinha; Arvind Bagga
Journal:  Indian J Pediatr       Date:  2008-11-21       Impact factor: 1.967

Review 5.  [Glucocorticoids in rheumatology].

Authors:  R Dziurla; F Buttgereit
Journal:  Z Rheumatol       Date:  2008-11       Impact factor: 1.372

Review 6.  Views on glucocorticoid therapy in rheumatology: the age of convergence.

Authors:  Frank Buttgereit
Journal:  Nat Rev Rheumatol       Date:  2020-02-19       Impact factor: 20.543

7.  Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.

Authors:  Cristian Labarca; Matthew J Koster; Cynthia S Crowson; Ashima Makol; Steven R Ytterberg; Eric L Matteson; Kenneth J Warrington
Journal:  Rheumatology (Oxford)       Date:  2015-09-18       Impact factor: 7.580

Review 8.  Glucocorticoid treatment in juvenile idiopathic arthritis.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-10-01       Impact factor: 2.631

Review 9.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

10.  Initiation of rheumatoid arthritis treatments and the risk of serious infections.

Authors:  Carlos G Grijalva; Lisa Kaltenbach; Patrick G Arbogast; Edward F Mitchel; Marie R Griffin
Journal:  Rheumatology (Oxford)       Date:  2009-11-11       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.